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Abstract and Keywords 
 
Abstract 
Hyperhomocysteinemia is associated with Alzheimer’s disease (AD). The causality of this association 
is controversial. In this study we tested the effect of a hyperhomocysteinemia-inducing diet in the 
ArcAβ transgenic AD mouse model. At 14 months of age, the hyperhomocysteinemia-inducing diet 
yielded higher plasma homocysteine levels in ArcAβ mice compared with wild-type mice. Plasma 5-
methyltetrahydrofolate (5-MTHF) in 14-month-old mice on hyperhomocysteinemia-inducing diet were 
lower in the transgenic than in the wild-type mice. The folate derivate 5-MTHF serves as cofactor in 
homocysteine metabolism. Oxidative stress, which occurs in the course of disease in the ArcAβ mice, 
consumes 5-MTHF. Thus, the transgenic mice may plausibly be more vulnerable to 5-MTHF-depleting 
effects of hyperhomocysteinemia and more vulnerable to hyperhomocysteinemia-inducing diet. This 
argues that AD pathology predisposes to hyperhomocysteinemia, i.e. as a facultative consequence of 
AD. However, we also observed that dietary-induced folate reduction and homocysteine increase was 
associated with an increase of plasma (young animals) and brain (older animals) Aβ concentrations. 
This suggests that the hyperhomocysteinemia-inducing diet worsened pathology in the transgenic 
mice. In conclusion, this data may argue that folate reduction and hyperhomocysteinemia may 
contribute to neurodegeneration and may also be triggered by neurodegenerative processes, i.e. 
represent both a cause and a consequence of neurodegeneration. Such a vicious cycle may be 
breakable by dietary or supplementation strategies increasing the availability of 5-MTHF. 
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Introduction 
Sporadic Alzheimer’s disease (AD) is the most common form of dementias. Higher age, female 
gender and presence of the apolipoproteinE4 allele have been identified as risk factors. In addition, 
hyperhomocysteinemia is independently associated with AD [1]. Factors like higher age, male gender, 
renal dysfunction, genetic variants, high methionine uptake via protein-rich food and deficiencies of 
folate, vitamin B12 and vitamin B6 are linked to hyperhomocysteinemia [2]. The nature of the 
relationship between hyperhomocysteinemia and AD is controversial [3-5]. 
Homocysteine is a toxic intermediate of methionine metabolism. It is either irreversibly metabolized by 
the vitamin B6-dependent transsulfuration pathway or is recycled to methionine by the folate- and 
vitamin B12-dependent remethylation pathway (Figure 1). Methionine can be activated to S-
adenosylmethionine (SAM), which serves as universal methyl-group donor, e.g. for DNA, RNA and 
protein methylation reactions. SAM is thereby converted to S-adenosylhomocysteine (SAH), which is 
further hydrolyzed to homocysteine in a reversible reaction. Although elevated plasma homocysteine 
levels have consistently been reported as an independent risk factor for AD [1, 6, 7] and predict 
cognitive decline in AD patients [8], several interventional trials have not observed beneficial effects of 
homocysteine-lowering strategies in AD [3, 9-11]. However, the recent VITACOG trial showed a highly 
significant reduction in brain atrophy as an effect of homocysteine-lowering vitamins in individuals with 
mild cognitive impairment [12]. In AD patients, high serum homocysteine levels are often accompanied 
by low serum folate levels [6, 13]. Low folate levels may be an additional independent AD risk factor 
[14, 15] and may independently correlate with cognitive decline in AD patients [8, 16]. Cerebrospinal 
fluid (CSF) folate levels were decreased in AD patients in some [17-19], but not all studies [20, 21]. 
CSF and brain SAM levels, which depend on the availability of folate (Figure 1), are decreased in AD 
[20, 22, 23]. Whether hyperhomocysteinemia is an independent causal AD risk factor or occurs as 
secondary epiphenomenon of neurodegeneration, is an important un-answered question. To test the 
hypothesis that changes of homocysteine metabolism occur during the natural course of 
neurodegeneration, we analyzed plasma homocysteine and folate levels and their association with 
brain and plasma Aβ1-40 and Aβ1-42 fractions in the ArcAβ mouse model. 
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Materials and Methods 
The ArcAβ mouse strain over-expresses human AβPP containing the Swedish double mutation (Swe; 
K670N; M671L) and the Arctic mutation (E693G) [24]. ArcAβ mice exhibit extracellular Aβ plaque 
deposition starting at 7 months of age followed by massive Aβ plaque formation and cerebral Aβ 
angiopathy between 9 and 15 months. These biochemical hallmarks are accompanied by progressive 
cognitive impairment of spatial memory starting at 6 months.  
In this study, 40 ArcAβ mice (18 female; 22 male) and 51 wild-type littermates (33 female; 18 male) 
were fed either normal diet (3g/kg methionine; 2mg/kg folic acid) or methionine-rich diet (MR; 20g/kg 
methionine, inducing hyperhomocysteinemia without folate depletion) from the age of three months 
until sacrificed at the age of 6 or 14 months, respectively. In-cage behaviour and body weight were 
monitored. Total plasma homocysteine and 5-MTHF were measured after cardiac puncture in terminal 
anaesthesia; other folate fractions were below the threshold of measurement [25, 26]. Brains were 
extracted and snap frozen. For the analysis of the Aβ fractions the brains were homogenized in liquid 
nitrogen, lysed in pre-cooled 2% SDS buffer pH=8.0 (2% SDS, 100mM TrisBase, 150mM NaCl, 1x 
protease and phosphatase inhibitor solutions (Roche)) and centrifuged for 30 min at 100’000xg at 8°C. 
Supernatants (= SDS-soluble brain Aβ fraction) were stored at -80°C until further measurements. 
Pellets were dissolved in 70% formic acid by ultra-sonication and centrifuged for 30 min at 100’000xg 
at 4°C. Supernatants (= SDS-insoluble brain Aβ fraction) were transferred to low-bind Eppendorf tubes 
and lyophilized. Pellets were resolved in 2% SDS buffer pH=8.0 and stored at -80°C until further 
measurements.  
Brain and plasma Aβ1-40 and Aβ1-42 fractions were measured with the Meso Scale Discovery 
System Multiplexed Aβ Ultra-Sensitive Assays (Meso Scale Diagnostics, LLC (Gaithersburg MD, 
USA)). Plasma homocysteine levels were not normally distributed and were therefore transformed to a 
logarithmic scale for statistical analysis. Metabolite levels were analyzed by Pearson’s correlation and 
by multivariate-ANOVA with the variables age, diet, genotype and gender followed by multivariate-
ANOVA of the age and diet subgroups with the variables genotype and gender. Animal experiments 
were approved by the Federal veterinary office and conducted according to the Swiss Law for Animal 
Protection. 
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Results 
In-cage behaviour, food intake and body weight were not associated with genotype or diet. As 
expected, the methionine-rich diet led to increased plasma homocysteine levels in both the 6- and the 
14-month-old animals (log plasma homocysteine at 6 months p=0.022, log plasma homocysteine at 14 
months p<0.001; Figure 2A). Plasma homocysteine levels did not differ between age groups, 
independent from the diet (Figure 2A). However, the 14-month-old ArcAβ mice on methionine-rich diet 
had higher plasma homocysteine levels than their wild-type littermates on the same diet (log plasma 
homocysteine p=0.006, Figure 2A).  
To gather further information on the reasons of stronger methionine-induced hyperhomocysteinemia in 
transgenic mice at a progressed stage of pathology, we next measured the concentrations of the main 
biological folate derivative, 5-MTHF. As expected, the methionine-rich diet group showed reduced 5-
MTHF levels (6 months p<0.001, 14 months p<0.001; Figure 2B). However, at 14-months of age, 5-
MTHF levels negatively correlated with homocysteine levels in the ArcAβ mice only (r=-0.861; 
p=0.001). Further, 5-MTHF was lower in males than in females p<0.001, but this was not associated 
with homocysteine plasma levels (Figures 2A and 2B). 
 
Aβ levels 
As expected, plasma Aβ1-40 and Aβ1-42 levels were higher in the 14-month-old ArcAβ mice (1619 ± 
350 pg/ml and 146 ± 56 pg/ml) than in 6-month-old ArcAβ mice (1288 ± 468 pg/ml and 92 ± 44 pg/ml; 
p=0.033 and p=0.006, respectively; Figure 3). In addition, in the 6-month-old animals, Aβ1-42 levels 
inversely correlated with plasma 5-MTHF levels (r=-0.521, p=0.027, Figure 4, which was not 
significant in the progressed, i.e. 14-month-old, animals (r=-0.164, p=0.465).  
Levels of both the SDS-soluble and the SDS-insoluble brain Aβ1-40 and Aβ1-42 fractions were below 
the detection limits in wild-type mice and in 6-month-old ArcAβ mice. In the 14-month-old ArcAβ mice, 
SDS-insoluble brain Aβ1-40 and Aβ1-42 were higher in animals on methionine-rich diet, which was 
significant for Aβ1-40 in the female mice only (F=11.715; p=0.027; Figure 5). Further explorative 
analyses revealed that, in these animals, SDS-insoluble brain Aβ1-40 (p=0.058 for trend) and SDS-
insoluble brain Aβ1-42 levels negatively correlated with plasma 5-MTHF levels (r=-0.905, p=0.013; 
Figure 6 and with plasma homocysteine levels for trend (r=0.808, p=0.051). 
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Discussion 
Hyperhomocysteinemia is a risk factor for AD. In animal models, hyperhomocysteinemia induced by 
folate depletion promotes AD pathology (4, 34). However, in patients low serum folate levels were 
observed as risk factor for cognitive decline independent from hyperhomocysteinemia questioning the 
role of homocysteine in folate-induced hyperhomocysteinemia in AD models (14, 15). We analyzed 
homocysteine and the major biological folate derivative, 5-MTHF, in an AD mouse model, both in the 
natural course and under nutritional conditions inducing hyperhomocysteinemia without manipulating 
diet folate concentrations. As major result, we observed a reduction of plasma 5-MTHF levels and an 
increase of plasma homocysteine levels in higher aged transgenic animals with progressed pathology  
in comparison to age-matched littermates. However, these differences between transgenic and control 
mice were only observable in the group on hyperhomocysteinemia-inducing diet, whereas in the 
normal diet group, no differences between genotypes were observed. We also found negative 
correlations of brain (progressed pathology) and plasma Aβ levels (early pathology) with 5-MTHF and, 
for trend, with homocysteine (progressed pathology) levels suggesting that a possible direct or indirect 
interaction between folate and homocysteine metabolism with Aβ may not be restricted to the CNS, 
but may take place on a systemic level.  
Importantly, oxidative stress and inflammation can deplete 5-MTHF, thereby increasing plasma 
homocysteine levels [27, 28]. Aβ induces oxidative stress and inflammation in the brain [29, 30]. Thus, 
Hoffman (2011) proposed that hyperhomocysteinemia is a consequence of folate depletion caused by 
oxidative stress [31]. In our study, under nutritional conditions elevating homocysteine plasma levels 
without folate depletion, mice with progressed neurodegeneration exhibited stronger 
hyperhomocysteinemia associated with lower 5-MTHF levels in comparison to wild-type littermates. 
This offers room to speculate on co-acting effects of neurodegeneration and hyperhomocysteinemia 
leading to 5-MTHF reduction. In the course of a vicious cycle, reduced 5-MTHF increases 
homocysteine, which itself promotes oxidative stress, 5-MTHF reduction and elevated Aβ-levels [32]. 
In line with our findings, another APP-transgenic mouse model at a progressed stage had higher 
plasma homocysteine levels compared to the wild-type animals [33], whereas in mice at early 
phenotypic stage or on standard laboratory chow [34], no association between genotype and plasma 
homocysteine levels were observed [35]. In accordance to our animal data, men have higher plasma 
homocysteine levels than women [13]. However, we could only speculate whether there are specific 
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differences explaining that some associations were restricted to one gender in our study, which also 
might be explained by chance regarding the decreased number of animals in gender subgroup 
analyses. 
Reduction of 5-MTHF levels leads to decreased remethylation of homocysteine to the methyl group 
donor SAM and higher levels of the SAM antagonist SAH, with the consequence of a reduced 
SAM/SAH-ratio (Figure 1). In addition to the above mentioned general aspects concerning 5-MTHF, 
homocysteine, oxidative stress and neurodegeneration, such effects on the SAM/SAH-ratio affect site-
specific methylation patterns of genes involved in Aβ generation in cell culture and in animal studies 
[4, 36, 37], e.g. leading to an increased expression of presenilin1 and increased brain Aβ levels in both 
wild-type mice and APP-transgenic mouse models [4, 38, 39]. Such increase of Aβ can be prevented 
by dietary SAM supplementation [4, 38, 40, 41] underlining the relevance of methylation processes 
and of 5-MTHF as co-factor for SAM-synthesis in AD pathophysiology. The data of our study suggests 
that the relation between low plasma folate levels, hyperhomocysteinemia and AD is not 
unidirectional. In the progressed transgenic mice, hyperhomocysteinemia-inducing diet led to lower 
folate and higher homocysteine blood levels compared to wild-type littermates suggesting that, on the 
one hand, the diet had a decisive influence on folate reduction and, on the other hand, that the 
transgenic genotype is associated with increased vulnerability to folate reduction under such 
nutritional conditions. The higher increase of homocysteine observed in the progressed transgenic 
mice on hyperhomocysteinemia-inducing diet might well have been secondarily to the lower folate 
levels when compared to wild-type mice with same age and on the same diet. Speculatively, the 
combination of oxidative stress in neurodegeneration and of the specific diet might best explain the 
folate reduction and the pronunciation of hyperhomocysteinemia in the progressed transgenic mice on 
hyperhomocysteinemia-inducing diet. As folate levels negatively correlated with Aβ, the current 
experiments suggest that such changes of folate levels may be pathophysiologically relevant. We 
conclude that the transgenic mice are more vulnerable to develop folate depletion and 
hyperhomocysteinemia under respective dietary conditions and that such biochemical changes 
contribute to AD-like pathology. Thus, changes of folate and homocysteine metabolism may be both, 
contributor to and consequence, of neurodegeneration. This may be a vicious cycle breakable by 
homocysteine-lowering vitamins as suggested by the VITACOG trial [12].  
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Figure Legends 
Figure 1 
The two pathways of homocysteine metabolism. In the remethylation pathway the methyl group from 
5-methyl-tetrahydrofolate (5-MTHF) is transferred to homocysteine by the vitamin B12-dependent 
enzyme methionine synthase (MS), producing methionine and tetrahydrofolate (THF). Methionine is 
activated to S-adenosylmethionine (SAM) by methionine adenosyltransferase (MAT) transferring 
adenosine from ATP. SAM acts as methyl group donor for a diversity of methylation reactions 
catalyzed by methyltransferases (MTs) producing S-adenosylhomocysteine (SAH), which is reversibly 
hydrolyzed to homocysteine by SAH hydrolase (SAHH). In the transsulfuration pathway, homocysteine 
is irreversibly degraded to cystathionine by the vitamin B6-dependent enzyme cystathionine-β-
synthase (CBS) and then further catalyzed to cysteine, a precursor of glutathione, by the vitamin B6-
dependent enzyme γ-cystathionase (CGL). 
 
Figure 2 
Metabolite concentrations of A) plasma homocysteine and B) plasma 5-MTHF of wild-type and ArcAβ 
mice on either control diet or methionine rich diet at the ages of 6 months and 14 months. Values 
represent mean ± standard deviation. Statistically significant difference between the two genotypes or 
genders is indicated (analysis of variance over all groups). 
 
Figure 3 
Concentrations of plasma Aβ1-40 and Aβ1-42 in ArcAβ mice on either control diet or methionine rich 
diet at the ages of A) 6 months and B) 14 months. Values represent mean ± standard deviation. 
Statistically significant difference between the two genotypes or genders is indicated (analysis of 
variance over all groups). 
 
Figure 4 
Correlation between plasma 5-MTHF and plasma Aβ1-42 in 6-month-old ArcAβ mice on either control 
diet (gray circles) or high methionine diet (green triangles). Pearson correlation r=-0.527, p=0.027, 
n=18. 
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Figure 5 
Concentrations of SDS-insoluble brain A) Aβ1-40 and B) Aβ1-42 in 14-months-old ArcAβ mice on 
either control diet or methionine rich diet. Values represent mean ± standard deviation. Statistically 
significant difference between the two genotypes or genders is indicated (analysis of variance over all 
groups). 
 
Figure 6 
Correlation between plasma 5-MTHF and SDS-insoluble brain Aβ1-42 levels in 14-month-old ArcAβ 
mice of both diet groups. Pearson correlation was calculated for females (green triangles; r=-0.905, 
p=0.013, n=6) and males (gray circles; r=-0.404, p=0.321, n=8). 
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